Effect of Continuous Renal Replacement Therapy Combined with Hemoperfusion on ICU Sepsis Patients
Objective To investigate the efficacy of continuous renal replacement therapy(CRRT)combined with hemoperfusion in the treatment of sepsis in intensive care unit(ICU).Methods A total of 78 patients with sepsis in ICU admitted to Tengzhou Traditional Chinese Medicine Hospital from September 2022 to September 2023 were selected as the research objects and were divided into a control group and an observation group according to random number table method,with 39 cases in each group.The control group was treated with hemoperfusion,and the observation group was treated with CRRT on this basis.Both groups were treated for 1 week.The clinical efficacy,renal function and inflammatory factor levels were compared between the two groups.Results The total effective rate of the observation group was 94.87%,higher than 76.92%of the control group,the difference was statistically significant(P＜0.05).After treatment,the levels of blood urea nitrogen and serum creatinine in the observation group were(12.39±1.54)mmol/L and(143.26±12.29)μmol/L,respectively,which were lower than(20.25±2.40)mmol/L and(195.41±16.54)μmol/L in the control group,the differences between the groups were statistically significant(P＜0.05).After treatment,the levels of C-reactive protein,interleukin-6,tumor necrosis factor-α and procalcitonin in the observation group were(10.53±1.65)mg/L,(20.26±2.69)ng/L,(10.50±1.67)ng/L and(0.53±0.11)ng/L,respectively,which were lower than(15.21±2.27)mg/L,(39.46±4.47)ng/L,(14.34±2.18)ng/L,(1.23±0.27)ng/L in the control group,and the differences between the groups were statistically significant(P＜0.05).Conclusion CRRT combined with hemoperfusion can improve renal function and control inflammation in patients with sepsis in ICU,which is worthy of clinical application.
SepsisContinuous renal replacement therapyHemoperfusionRenal function
NETL
NSTL
万方数据
